Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global allogenic CAR-T cell therapy market size was valued at USD 0.87 billion in 2023, driven by the rising advancements in gene technology across the globe. The market is expected to grow at a CAGR of 15.6% during the forecast period of 2024-2032, with the values likely to attain USD 3.24 billion by 2032.
Allogeneic CAR-T cell technology involves genetically engineered T-cells from unrelated healthy donors to recognize antigens on cancer cells. These modified cells use the body's immune system to identify and target cancer cells. This approach is intended to improve the safety and effectiveness of the treatment by looking for the difficulties related to personalized autologous treatments. It also aims to increase the possibility of application and effectiveness in targeting various kinds of cancer.
Rising Prevalence of Cancer Significantly Drives the Market Growth
The American Cancer Society revealed that the United States alone recorded around 1,958,310 new cancer cases while 609,820 cancer-related deaths were observed in 2023. The increasing incidence and prevalence of cancer along with the growing number of patients who display failure in response to multiple therapies fuel the allogenic T-cell therapy market growth across the world.
Furthermore, more cases of cancer are being diagnosed in both geriatric and pediatric patients, bolstering the demand for effective and healthier treatment to enhance the quality of life of the patient.
Increasing Investment and Research Initiatives to Boost Rising Allogenic CAR-T Cell Therapy Market Demand
Allogeneic CAR-T cell therapy is gaining attention with rising investment and research activities in various cancer types. This investment is being spurred by improved methods of genetic engineering, fine-tuning production procedures, and widened usage of enzymatic products in the treatment of solid cancers apart from blood cancers. The rising emphasis on investments and research is a key driver of market growth as it fosters innovation, therapeutic outcomes, and the international expansion of allogeneic CAR-T cell therapies.
Key Trends | Impact |
Advancements in Gene Editing Technologies | Recent developments in gene editing technology like CRISPR/Cas9 help make necessary DNA modifications that make allogeneic CAR-T cells safer and more efficient. These can go for genes that cause graft-versus-host disease and improve CAR-T cells' prospects to identify and destroy cancer cells. This connection also helps to overcome immuno-rejection issues and side effects, which makes these therapies safer and more useful. |
Preference for Combination Therapies | Combination strategies focus on using allogeneic CAR-T cells and other immunotherapies or chemotherapy to enhance therapeutic effects. It also improves CAR-T cells’ therapeutic abilities, eliminates cancer immunity, and broadens the treatment spectrum. Combined with other types of immune checkpoint inhibitors, chemotherapy or radiation lowers tumor mass and provides new options for many cancers. |
Clinical Trial Expansion | Allogeneic CAR-T cell therapies are advanced to several clinical trials globally to determine the safety and effectiveness of the treatment across different patients and different types of cancer. This expansion is a response to logistical and manufacturing concerns related to personalized cell therapies that could serve as the catalysts for official recognition and standard use of these therapies as treatments for cancer. |
Personalized Manufacturing Platforms | More individualized manufacturing solutions for allogeneic CAR-T cells are driving changes in production processes due to automation as well as applications of closed-system technologies. They minimize variability, human intervention, and contamination, hence providing reproducible therapies. It also helps in expanding these therapies at cheaper rates and making them shift from clinical trials to broader practice in clinics. |
In April 2024, CARibou Biosciences received FDA approval for its CD19-specific allogeneic CAR-T CB-010 for lupus nephritis and extrarenal lupus treatment. The latest approval is based on the ANTLER trial for third-line treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first clinical trial of GALLOP Phase 1 is expected to start by the end of 2024, as it aims to assess the effectiveness of CB-010 in targeting CD19-positive B cells that are responsible for autoantibody synthesis and autoimmune response reinforcement. The therapy prospect is to develop a new treatment plan for lupus with a focus on the problems, such as organ damage. This trial will also address the matching between donors and patients in a partial HLA to boost clinical results.
In July 2023, Poseida Therapeutics received FDA approval on the investigational new drug for P-CD19CD20-ALLO1, which is an allogeneic dual CAR-T cell product for the treatment of relapsed or refractory B-cell malignancies. It employs Poseida’s non-viral piggyBac® DNA Delivery System to add two functional CARs and intends to address the antigen escape in CD19-only products. Phase 1 will involve 70 patients and is primarily designed to evaluate the safety, tolerability, and, to some extent, efficacy.
Market Breakup by Therapeutic Area
Market Breakup by Indication
Market Breakup by Source of Cell
Market Breakup by Region
Market Segmentation by Therapeutic Area is Projected to Experience Significant Growth
Based on the therapeutic areas, the market is divided into oncological disorders, neurological disorders, musculoskeletal disorder, autoimmune / inflammatory disorders, post-transplant infections and others. Oncological disorders are expected to hold a significant market share in the forecast period. This can be attributed to the rising incidence of cancer and cancer-associated mortality rates across the globe.
Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America dominates the market owing to the availability of early and established healthcare systems, increased adoption of innovative therapies, and favorable regulatory environments that support clinical trials and product launches.
Europe also holds a substantial share as it is equipped with a well-developed infrastructure to conduct research and development activities. Cooperation between universities and industries, and reasonable reimbursement policies also aid market enhancement. The Asia Pacific is expected to become another prominent market for allogeneic CAR-T cells due to factors such as growing concern about the healthcare budget, the increasing incidence of cancer, and the growing availability of innovative treatment options.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Artiva Biotherapeutics Inc
The company Artiva Biotherapeutics was established in 2019 and is in San Diego. It is engaged in the development of allogeneic natural killer (NK) cell therapies. Their pipeline consists of the NK cell therapy AB-101, which is in different phases of the clinical trial for different types of cancer, and the AB-201 program for different solid tumors, which is still in the preclinical stage. These therapies are used to boost anti-tumor activity and may be added to MAbs and other treatments.
Allogene Therapeutics Inc.
Allogene Therapeutics was founded in 2017 and is in San Francisco, California. This biotechnology company focuses on allogeneic CAR-T cell therapies. The company’s pipeline comprises ALLO-501/ALLO-501A for the treatment of non-Hodgkin lymphoma, ALLO-715 for multiple myeloma cancer, the CD70-directed ALLO-316 for renal cell carcinoma and other solid cancers, along with ALLO-605, a TurboCAR™ therapy that targets BCMA. These commercial therapies are intended to replace the need for manufacturing treatments tailored to a particular patient’s tumor type.
Atara Biotherapeutics Inc.
Atara Biotherapeutics was established in 2012 and is proposing allogeneic CAR-T and T-cell immunotherapies. ATA3271 is working for solid tumors with Bayer for targeting mesothelin, and ATA3219 for CD19-positive B-cell malignancies. Atara employs EBV T-cell lines to develop drugs for cancer, autoimmune, or viral disease treatments.
Cellenkos, Inc.
Founded in 2016 and based in Houston, USA, Cellenkos engages in the generation of allogeneic, cord blood-derived T regulatory (Treg) cell therapies. CK0801 for inflammatory and autoimmune diseases and CK0802 for GvHD and inflammatory diseases are their main products. Cellenkos uses the immunosuppressive property of Treg cells to control immune reactions.
Other companies include Cell2Cure Apps, Celularity, Inc., Cellular Biomedicine Group, Chabiotech Co., Ltd., and CRISPR Therapeutics AG.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapeutic Area |
|
Breakup by Indication |
|
Breakup by Source of Cell |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124